CA
NZ
UK
AU
IND
US
The presentation will specifically highlight baseline characteristics correlated with a confirmed loss of 15 letters in Best Corrected Visual Acuity (BCVA) among patients with geographic atrophy. BCVA is a standard clinical measure of vision quality used extensively in ophthalmology trials, and a 15-letter loss …
The AAIC data specifically showed consistent results across multiple prespecified clinical endpoints, a notable finding given that this program had faced a significant setback earlier this year. In May 2026, Ionis disclosed that the CELIA trial's topline readout did not meet its primary endpoint, …
Metastatic castration-resistant prostate cancer represents a challenging treatment setting, as patients in this population have typically progressed despite standard androgen deprivation therapy, creating ongoing need for new combination approaches that can extend disease control. Rinzimetostat's advancement into a Phase 3 combination trial with darolutamide, …
Recurrent pericarditis is a condition characterized by repeated episodes of inflammation of the pericardium, the membrane surrounding the heart, causing significant pain and reduced quality of life for affected patients. Current treatment options for recurrent cases remain limited, making a therapy capable of substantially …
The data specifically showed that when isolating patients who achieved therapeutic trough plasma concentrations of the drug, neflamapimod demonstrated statistically significant slowing of DLB progression, along with durable preservation of basal forebrain volume on MRI over 48 weeks. This kind of concentration-based subgroup analysis …
The preliminary figures showed revenue of €300.1 million for the first half of the year, alongside an adjusted EBITDA loss of €42.7 million. Reporting an EBITDA loss, rather than positive earnings, represents a significant deterioration for a company of Evotec's scale and maturity in …
The scale of today's decline is directly tied to the ownership structure embedded in the merger: existing Matinas stockholders will retain only roughly 9% ownership in the reorganized company. A retained stake this modest signals that the substantial majority of the combined company's future …
Under the terms of the sale, Matinas will receive $4.0 million in upfront cash, a relatively modest sum that reflects the transaction structure's heavier reliance on contingent, milestone-based consideration rather than a larger immediate payment. This structure is a common approach in biotech asset …
The long-term extension data, drawn from 34 patients with up to 15.9 months of drug exposure, showed a 92% reduction in treated bleeding events, a substantial improvement speaking to sutacimig's potential to meaningfully reduce the bleeding burden faced by patients with this rare and …
The Phase 2/3 designation itself reflects the transitional nature of sutacimig's current development stage: the company has completed a Phase 2 long-term extension study while simultaneously planning its registration-directed Phase 3 trial, a designation that captures both the maturity of the existing dataset and …
Please wait processing your request...